FIRST CHANCE BEST CHANCE
Planning for biologic fusion is as
important as planning for stabilisation.
THINK: PATIENT, PROCEDURE AND SITE CHALLENGE
Challenge of Patient
Patients have different comorbidities such as diabetes, age, smoking, etc.
Challenge of Site
- Blood supply – Does your patient have scar tissue and disrupted access to nutrients of blood supply?
- Does the site have inoculation with bacteria such as in open trauma cases?
- Does the site have poor access to cells due to treatments such as radiation therapy?
- Are you able to adequately decorticate the site to provide adequate access to bone forming cells that will aid in healing?
Challenge of Procedure
- Do you have adequate access to local bone autograft?
- In tumour situations, local bone autograft may not be suitable
- Do you need just bone void fillers/extenders or do you need an autograft replacement?
Your patients’ needs define your product choice.
Why do you need multiple bone grafting options? You need grafting options that support the level of activity required for the challenge of patient/site/procedure.
Would you like to receive more information from Medtronic biologics? If so, please complete the Biologics Information Request form.
- High Proven Osteoinductivity1-2
Proprietary D-Min™ Processing: Preserves the osteoinductive proteins.
Demonstrated efficacy: 26 years of clinical history in nearly 1 million procedures worldwide.2
Fiber technology proven to be osteoconductive in a preclinical outcomes study.3
The Mastergraft™ family of products are osteoconductive, resorbable scaffolds that may be used as bone graft substitutes and to extend autograft.
Histological scoring table based on images from Edwards, JT et al. Clin Orthop Relat Res. 1998; 357:219-228.
Based on internal sales data.
Martin GJ, Boden SD, Titus L, Scarborough NL. New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. Spine. 1999;24(7):637-645.